Abstract library

349 results for "Predict".
#2216 Predicting Response to PRRT: Development and Validation of a Blood-Based Predictive Biomarker
Introduction: We have developed a blood-based tool (gene expression analysis and tumor grade) for predicting PRRT efficacy.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Professor Mark Kidd
#1524 Is mTOR Pathway Activity a Good Predictor for Everolimus Therapy? A Pilot Study to Build Up a Phase II Trial in Pancreatic Neuroendocrine Neoplasias (pNENs)
Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: PD Dr. Patricia Grabowski
#1677 A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Non-Functional Pancreatic Neuroendocrine Tumors.
Introduction: Surgical resection is the preferred treatment for NF-pNET, however recurrence still occurs frequently after curative surgery, worsening prognosis of patients.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.D. Cansu Genc
#320 Predictors of Clinical Response to Everolimus in Patients with Well-differentiated Metastatic Pancreatic NETs
Introduction: Everolimus (E) is an mTOR inhibitor with promising antitumor activity in patients with NETs. Predictor factors of response could improve the clinical use of this compound.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Cristina De Martino
#353 Pattern and Clinical Predictors of Lymph Node Involvement in Neuroendocrine Neoplasms of the Pancreas
Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are often indolent without pathological lymph node metastasis (pN1). Therefore, in patients with low risk of pN1, a lymphadenectomy could be avoided.
Conference:
Category: Basic
Presenting Author: Stefano Partelli
#1879 A Hybrid Clinical Molecular Nomogram Accurately Predicts Survival in PRRT Treated GEP-NETs
Introduction: Clinical assessment has limited prognostic ability. Mathematical tools –nomograms- that incorporate multiple parameters are more effective. Novel transcriptomic data has added value in defining NET biology in tissue and blood. A blood multigene expression analysis test is effective as a molecular prognostic marker for PFS.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Professor Mark Kidd
Authors: Kidd M, Bodei L, Severi S, Drozdov I, ...
#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour
Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Silvia Ortolani
#1436 Up-Regulation of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase (IDO) with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia
Introduction: Data from a considerable number of malignancies demonstrate that depletion of the essential amino acid tryptophan via induction of the immuno-regulatory enzyme Indoleamine-2,3-dioxygenase (IDO) serves as an important tumour escape strategy and is of prognostical importance.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr René Pschowski
Authors: Pschowski R, Pape U F, Fusch G, Jann H, ...
#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET
Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Jerome Cros
Authors: Bucau M, Cros J, Raffenne J, Rebours V, ...
#725 Contrast-Enhanced Ultrasonography (CEUS) Predicts the Effectiveness of Anti-Angiogenic Therapies in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Liver metastases (LM) from neuroendocrine tumors (NETs) exhibit a typical hypervascular pattern in the arterial phase on CEUS, allowing for a differential diagnosis between NET and non-NET LM. Medical therapy includes agents acting on angiogenesis and vascularization which may result in a change in CEUS findings.
Conference: 10th Annual ENETS Conference (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Antonella Di Sarno
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.